A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1005 | Th1002 | Cetuximab | Heavy chain:QVQLKQSG Full view | 243 | IIIc | Cancer | Erbitux | ImClone Systems Inc | Sterile, clear, colorless liquid of pH 7.0-7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates | Intravenous infusion | Antineoplastic Agents | Epidermal growth factor receptor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
| 1074 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Epogen | Amgen Inc. | Sterile, colorless liquid | Subcutaneous Injection | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1078 | Th1013 | Epoetin alfa | APPRLICDSRVLERYLLEAK Full view | 166 | Ib | Hematological | Procrit | Ortho Biotech | Sterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution | Intravenous(IV) or Subcutaneous (SC) administration. | Anti-anemic Agents, Hematinics | Erythropoietin receptor |
| 1194 | Th1025 | Intravenous Immunoglobulin | IGG1:PSALTQPPSASGSLG Full view | 250 | Ia | Immunological | Flebogamma | Instituto Grifols SA | Sterile, clear or slightly opalescent and colorless to pale yellow, liquid | Intravenous infusion | Immunosuppressive Agents, Immunologic factors, Anti-infective agents | High affinity immunoglobulin gamma Fc receptor I,High affinity immunoglobulin gamma Fc receptor IB,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc reg |
| 1341 | Th1049 | Interferon beta-1a | MSYNLLGFLQRSSNFQCQKL Full view | 166 | Ib | Cancer/Infectious/Immunological | Avonex | Biogen Inc | Lyophilized powder vial, Sterile liquid as single used prefilled syringe and also available as single use prefilled autoinjector. | Intramuscular Injection | Immunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1379 | Th1058 | Interferon alfacon-1 | CDLPQTHSLGSRRTLMLLAQ Full view | 165 | Ib | Immunological/Infectious | INFERGEN | Kadmon Pharmaceuticals, LLC. | Sterile, clear, colorless, preservative-free liquid | Subcutaneous Injection | Antiviral Agents and Immunosuppressive Agents | Interferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
| 1389 | Th1062 | Rituximab | Heavy Chain: QVQLQQP Full view | 664 | IIa | Cancer/Immunological | Rituxan | Biogen Idec Inc., and Genentech USA, Inc | Sterile, clear, colorless, preservative-free liquid concentrate |  Intravenous administration | Antineoplastic Agents, Immunologic Factors and Antirheumatic Agents | B-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c, Receptor tyrosine-protein kinase erbB-2,Epidermal growth factor receptor,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor I |
| 1465 | Th1089 | Palivizumab | VH region: QVTLRESG< Full view | 120 | IIIa | Infectious | Synagis | MedImmune | Sterile, preservative-free liquid solution | Intramuscular injection | Antiviral Agents | N.A. |
| 1474 | Th1094 | Panitumumab | N.A. Full view | 0 | IIa | Cancer | Vectibix | Amgen Inc | Sterile, colorless, pH 5.6 to 6.0 liquid for intravenous (IV) infusion, which may contain a small amount of visible translucent-to-white, amorphous, proteinaceous, panitumumab particulates | N.A. | N.A. | Epidermal growth factor receptor |
| 1550 | Th1119 | Tocilizumab | N.A. Full view | 0 | IIa | Immunological | ACTEMRA | Genentech | Sterile, preservative-free solution, colorless to pale yellow liquid, with a pH of about 6.5 | Intravenous infusion, Subcutaneous injection | N.A. | Interleukin-6 receptor subunit alpha |
| 1560 | Th1121 | Pertuzumab | light chain DIQMTQSP Full view | 664 | IIIc | Cancer | Perjeta | Genentech | Sterile, clear to slightly opalescent, colorless to pale brown liquid | Intravenous infusion | Monoclonal antibodies | Receptor tyrosine-protein kinase erbB-2 |
| 1624 | Th1137 | Teduglutide | HGDGSFSDEMNTILDNLAAR Full view | 33 | Ia | Malabsorption disorder | Gattex | NPS Pharmaceuticals, Inc | Clear, colorless to light-straw–colored liquid. | Subcutaneous injection | N.A. | Glucagon-like peptide 2 receptor |
| 1627 | Th1138 | Raxibacumab | N.A. Full view | 0 | IIa | Immunological/Infectious | RAXIBACUMAB | GSK | Sterile, liquid formulation in single-dose vials | N.A. | Anti-Infective Agents and Monoclonal antibodies | Protective antigen |
| 1636 | Th1142 | Obinutuzumab | N.A. Full view | 0 | IIb | Cancer | Gazyva | Genentech | Sterile, clear, colorless to slightly brown, preservative free liquid concentrate | Intravenous infusion | Antineoplastic Agents | B-lymphocyte antigen CD20 |
| 1768 | Th1186 | Human rabies virus immune globulin | NA Full view | 0 | IIIa | Infectious Disease | Hyperab Rabies Immune Globulin Human | Cutter Med & Biol, Division Of Miles Canada Ltd. | Liquid | Intramuscular | NA | NA |
| 1770 | Th1186 | Human rabies virus immune globulin | NA Full view | 0 | IIIa | Infectious Disease | Imogam Rabies Inj 150unit/ml | Pasteur mÉrieux Serums Et Vaccins, s.a. | Clear, pale yellow to light brown liquid | Intramuscular | NA | NA |
| 1772 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Hyp Rho D Inj 16.5% | Cutter Med & Biol, Division Of Miles Canada Ltd. | liquid | Intramuscular | NA | NA |
| 1779 | Th1187 | Human Rho(D) immune globulin | NA Full view | 0 | IIIb | Immunological Disorders | Winrho Sdf (liquid Formulation) | Aptevo Biotherapeutics Llc | liquid | Intramuscular; Intravenous | NA | NA |
| 1793 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Gamastan | Cutter Med & Biol, Division Of Miles Canada Ltd. | liquid | Intramuscular | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1795 | Th1190 | Immune Globulin Human | IGG1: PSALTQPPSASGSL Full view | 1338 | IIIb | Immunological Disorders | Hyqvia | Baxalta Us Inc. | Liquid | Intravenous infusion | Immunologic Factors; Immunosuppressive Agents; Anti-Infective Agents | High affinity immunoglobulin gamma Fc receptor I; High affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5. |
| 1813 | Th1204 | Ofatumumab | Ofatumumab Heavy Cha Full view | 483 | IIIc | Cancer | Arzerra | Glaxo Smith Kline Llc | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | |
| 1814 | Th1205 | Obiltoxaximab | NA Full view | 0 | IIIa | Infectious Disease | Anthim | Elusys Therapeutics, Inc. | Liquid | Intravenous infusion | NA | NA |
| 1815 | Th1206 | Nivolumab | Heavy Chain Sequence Full view | 710 | IIIc | Cancer | Opdivo | E.R. Squibb & Sons, L.L.C. | Liquid | Intravenous | Antineoplastic and Immunomodulating Agents | Programmed cell death protein 1 |
| 1826 | Th1216 | Anthrax immune globulin human | NA Full view | 0 | IIa | Immunological Disorders | ANTHRASIL | Cangene Corporation | Liquid | Intravenous | Plasma derivative | Protective antigen |
| 1831 | Th1221 | C1 Esterase Inhibitor (Recombinant) | NA Full view | 0 | IIa | Cardiac Disorders | Ruconest | Tjoapack Netherlands Bv | Powder and liquid for solution | Intravenous | Blood and Blood Forming Organs | Complement C1r subcomponent, Complement C1s subcomponent, Plasma kallikrein, Coagulation factor XII, Prothrombin, Coagulation factor XI, Tissue-type plasminogen activator |
| 1850 | Th1237 | Somatropin recombinant | FPTIPLSRLFDNAMLRAHRL Full view | 191 | Ib | Hormonal Disorders | NutropinAQ | Genentech Inc. | Sterile liquid | Subcutaneous | Hormones, Hormone Substitutes, and Hormone Antagonists | Growth hormone receptor, Prolactin receptor |